Time to Reframe Indonesia’s Medicine Pricing Debate

Few issues in Indonesian healthcare generate as much recurring frustration as medicine prices.

Patients complain that medicines are unaffordable. Policymakers worry about the long-term sustainability of BPJS Kesehatan. Hospitals face growing financial pressure. Pharmaceutical companies argue that public discussions often ignore the operational realities of supplying a vast and fragmented market.

Yet after years of debate, the conversation still tends to fall into familiar , and overly simplistic, narratives: medicines are “too expensive,” pharmaceutical companies are “overprofiting,” doctors are driving up costs through prescribing behavior, or tighter price controls alone will solve the problem.

The reality is considerably more complicated.

Since the launch of JKN in 2014, Indonesia has effectively operated two pharmaceutical markets at the same time.

The first is the BPJS/JKN ecosystem ; a tightly managed environment built around national formularies, e-catalogue procurement, INA-CBG reimbursement ceilings, and sustained downward pressure on medicine prices.

The second is the private and specialty-care market, where branded products, hospital financing models, prescribing dynamics, and fragmented purchasing patterns create a very different set of incentives.

Understanding the interaction between these two systems is increasingly important because many of the tensions now visible across Indonesia’s healthcare sector appear to stem from precisely that divide.

Within the BPJS segment, pricing negotiations and centralized procurement have, in many cases, succeeded in lowering acquisition costs for essential medicines. But aggressive price compression has also introduced new pressures: supply sustainability, stock reliability, participation incentives for manufacturers, availability of innovative therapies, and operational strain across the supply chain.

At the same time, patient experiences outside the BPJS environment can look entirely different.

In private hospitals and specialist-care settings, medicine costs may rise sharply depending on the treatment setting, distribution arrangements, brand positioning, and provider-level economics. As a result, public perception of “high drug prices” may not always reflect the realities of public-sector procurement.

This helps explain why Indonesia’s pharmaceutical debate is no longer simply about whether medicines are “cheap” or “expensive.” Increasingly, it is about whether incentives across the healthcare system remain properly aligned.

One particularly important ( and still under-discussed) issue concerns the role pharmaceuticals now play in healthcare financing itself. Across many markets, medicines are no longer viewed solely as clinical inputs. In some segments, they have also become economically significant components of provider sustainability.

That distinction matters.

If parts of the healthcare system depend heavily on pharmaceutical margins to support operations, then pricing behavior, treatment pathways, procurement strategies, and product selection will naturally evolve around those incentives ... regardless of how many formal price controls exist on paper.

Similarly, discussions around affordability often blur the distinction between manufacturer pricing and final patient pricing. The two are not equivalent.

Patient-facing prices are shaped by a much broader ecosystem involving procurement structures, reimbursement design, inventory risk, distribution economics, dispensing practices, and provider financing models.

This is also why international comparisons can quickly become misleading.

Claims that certain medicines are substantially cheaper in neighboring countries may sometimes be true at the retail level, while overlooking major differences in procurement architecture, healthcare financing, provider incentives, and market scale.

For policymakers, the implication is important: isolated interventions are unlikely to resolve the issue on their own. Price controls without adequate supply incentives may worsen shortages. Procurement reform without provider payment reform may simply shift distortions elsewhere. And public-sector savings that are not aligned with private-sector incentives may create new forms of downstream cost inflation.

Indonesia therefore may not need another fragmented debate about medicine prices alone.

What it may need instead is a broader discussion about how pharmaceutical policy, provider incentives, health technology assessment, affordability, and long-term healthcare financing interact within the same system.

This is not a simple issue. But it is one that likely deserves a more nuanced national conversation than it has often received.

The countries that have managed pharmaceutical affordability most effectively are rarely those that focused only on lowering prices. More often, they are the ones that aligned incentives coherently across the healthcare system itself.

Indonesia may now be approaching that same strategic crossroads.